Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...

The discussion surrounding GLP-1 medications needs to change to one that emphasizes science-based research and compassion.

As blockbuster GLP-1 injectables like Mounjaro, Wegovy and Ozempic gain traction in India, doctors stress that careful ...

GLP-1s are basically appetite’s off-switch: suddenly you’re “full” after three bites. Congrats on the smaller meals and ...

Phenomix's MyPhenome test continues to demonstrate predictive accuracy in identifying which patients are most likely to respond to GLP-1 therapies such as semaglutide. Studies presented at Obesity ...

Since we know that eating less food often means getting fewer nutrients, a high-quality multivitamin acts as an insurance ...

Learn how to prevent muscle loss while taking GLP-1 medications, with expert tips on protein intake, strength training, and ...

GLP-1 receptor agonists like semaglutide and tirzepatide have redefined what’s possible in the treatment of obesity and metabolic syndrome. These medications have shown remarkable results in appetite ...

Our work continues on behalf of TRICARE For Life beneficiaries. Learn the latest, and find out how to share your story with ...

At a White House event Thursday, President Trump announced deals with drugmakers Novo Nordisk and Eli Lilly to offer their popular GLP-1 obesity and diabetes drugs at lower prices for some Americans, ...

SAN DIEGO Dec 2 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans, animals and ...